Steroid hormones induce HMG1 overexpression and sensitize breast cancer cells to cisplatin and carboplatin

AUTOR(ES)

He, Qing

FONTE

The National Academy of Sciences

RESUMO

Cisplatin is an anticancer drug that has enjoyed remarkable success against testicular tumors, but dose limiting side-effects have limited its application against a broader range of cancers. Previous studies have shown that high-mobility group (HMG) domain proteins such as HMG1 sensitize cells to cisplatin by shielding its major DNA adducts from nucleotide excision repair. Estrogen treatment increases HMG1 mRNA levels in breast cancer MCF-7 cells. Herein, we describe that treatment of human cancer cells having steroid hormone receptors with the appropriate hormone, estrogen and/or progesterone, significantly increases the potency of cisplatin and its analogue carboplatin by causing the overexpression of HMG1. These findings suggest that the proper combination of these drugs, which are already approved by the Food and Drug Administration, could have potential benefit in treating tumors such as ovarian or breast that carry the hormone receptors.

Documentos Relacionados

• High affinity binding of proteins HMG1 and HMG2 to semicatenated DNA loops
• Nonhistone proteins HMG1 and HMG2 unwind DNA double helix.
• Physiologic effects of steroid hormones and postmenopausal hormone replacement on the female breast and breast cancer risk.
• Loss of chromosomal high mobility group proteins HMG1 and HMG2 when mouse neuroblastoma and Friend erythroleukemia cells become committed to differentiation.
• Upregulation of HMG1 Leads to Melanoma Inhibitory Activity Expression in Malignant Melanoma Cells and Contributes to Their Malignancy Phenotype